Patritumab is a recombinant human monoclonal antibody that specifically targets ERBB3, exhibiting neutralizing properties. This antibody effectively synergizes with Cetuximab to inhibit the phosphorylation of key signaling proteins including EGFR, HER2, HER3, ERK, and AKT. Through its action, Patritumab induces apoptosis and inhibits tumor growth, demonstrating significant efficacy in preclinical models of pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Patritumab is a valuable tool for research focused on the molecular mechanisms of cancer progression and therapeutic antibody development.
Patritumab is a recombinant human monoclonal antibody that specifically targets ERBB3, exhibiting neutralizing properties. This antibody effectively synergizes with Cetuximab to inhibit the phosphorylation of key signaling proteins including EGFR, HER2, HER3, ERK, and AKT. Through its action, Patritumab induces apoptosis and inhibits tumor growth, demonstrating significant efficacy in preclinical models of pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Patritumab is a valuable tool for research focused on the molecular mechanisms of cancer progression and therapeutic antibody development.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
